European Marketing Authorization for Pediatric Slenyto® for the treatment of insomnia in children with Attention Deficit Hyperactivity Disorder (ADHD).
We are pleased to share that Neurim Pharmaceuticals has received European Marketing Authorization for Pediatric Prolonged-Release Melatonin (Slenyto®) for the treatment of insomnia in children with Attention Deficit Hyperactivity Disorder (ADHD).
This new indication provides an important treatment option for more patients, helping them achieve better sleep and brighter days with Slenyto®.
Read our press release